)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Biogen Pharmachem Industries
Biogen Pharmachem Industries (531752) investor relations material
Biogen Pharmachem Industries Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary3 Nov, 2026
Executive summary
Q2 FY26/27 revenue was ₹28.33 lakh and net profit was ₹25.73 lakh; H1 revenue was ₹72.67 lakh and net profit was ₹47.87 lakh.
The Board approved the unaudited standalone results for the quarter and half year ended September 30, 2026.
Financial highlights
Q2 revenue was ₹28.33 lakh vs. a loss of ₹10.49 lakh in Q2 FY25/26; H1 revenue fell to ₹72.67 lakh from ₹143.79 lakh.
Q2 profit before tax and net profit were both ₹25.73 lakh, vs. a loss of ₹49.15 lakh in Q2 FY25/26.
H1 profit before tax and net profit were both ₹47.87 lakh, vs. ₹85.33 lakh in H1 FY25/26.
Segment performance
Operations comprise one segment; no separate segment results were presented.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Biogen Pharmachem Industries
- Revenue contracted sharply as profits narrowed; outlook centered on commodity trading and wind power.531752
Q4 06/07 - FY08 trading contracted sharply, with conflicting reported profit figures and planned wind-power expansion.531752Q4 07/08
- Trading expanded, but a ₹43.33m loss and accumulated-loss risks overshadowed growth plans.531752Q4 08/09
- Net loss narrowed sharply, while preference warrants and corporate advances expanded the balance sheet.531752Q4 09/10
- FY12 loss narrowed, but weak markets constrained revenue and management looked to rebuild turnover.531752Q4 11/12
- Zero operating revenue and a wider FY2012-13 loss contrasted with a sharp rise in investments.531752Q4 12/13
- Nil operating revenue, a ₹1.30 million loss and sharply higher short-term borrowings marked FY14.531752Q4 13/14
- No operations, nil operating revenue, and a ₹1.33m FY15 net loss amid working-capital constraints.531752Q4 14/15
- Nil revenue and working-capital constraints kept operations inactive; FY15/16 net loss was ₹281,764.531752Q4 15/16
Next Biogen Pharmachem Industries earnings date
Q3 26/278 Feb, 2027
Biogen Pharmachem Industries
Next Biogen Pharmachem Industries earnings date
Q3 26/278 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Biogen Pharmachem Industries Limited is a pharmaceutical company engaged in the trading and distribution of bulk drugs, intermediates, and chemical products. The company focuses on supplying raw materials used in the manufacturing of pharmaceutical formulations. Its operations support pharmaceutical and chemical industry clients by sourcing and delivering essential inputs for production. Biogen Pharmachem Industries Limited may also engage in allied business activities related to healthcare and chemical sectors. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.